ARQT - Arcutis Biotherapeutics

-

$undefined

N/A

(N/A)

Arcutis Biotherapeutics NASDAQ:ARQT Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis' robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company's lead product candidate, topical roflumilast, has the potential to become the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.

Location: | Website: arcutis.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.354B

Cash

330.6M

Avg Qtr Burn

-41.91M

Short % of Float

29.15%

Insider Ownership

2.15%

Institutional Own.

-

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

ZORYVE® (Roflumilast foam 0.3%) Details
Skin disease/disorder, Seborrheic dermatitis

Approved

Quarterly sales

ZORYVE® (ARQ-151) topical roflumilast cream (PDE4 Inhibitor) Details
Psoriasis, Skin disease/disorder, Chronic obstructive pulmonary disease, Pulmonary hypertension

Approved

Quarterly sales

Approved

Quarterly sales

PDUFA

Approval decision

sNDA

Submission

ARQ-255 topical ivarmacitinib (JAK1 inhibitor) Details
Skin disease/disorder, Alopecia areata

Phase 1b

Data readout

ARQ-252 (JAK1i) Details
Skin disease/disorder, Eczema

Failed

Discontinued

Failed

Discontinued